GlassScriptPhysician profile
Elmer L Quintero
NPI 1952628133
$154,860.57
in general payments reported to CMS, 2019-2025
13 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $7,426 · 2021: $2,894 · 2022: $5,339 · 2023: $15K · 2024: $55K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Travel and Lodging: $9,016 · Food and Beverage: $3,732 · Consulting Fee: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,230.38 |
| Travel and Lodging | $9,016.04 |
| Food and Beverage | $3,732.33 |
| Consulting Fee | $1,380.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $88,905.83 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $51,984.30 | 2019-2025 | Invega Sustenna |
| Bioxcel Therapeutics, INC. | $10,523.91 | 2023-2024 | Igalmi |
| E.R. Squibb & Sons, L.L.C. | $1,764.11 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $514.95 | 2024-2025 | Uzedy |
| Alkermes, INC. | $505.18 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Indivior INC. | $267.08 | 2021-2023 | Perseris |
| Lundbeck LLC | $193.39 | 2022-2024 | Abilify Maintena |
| Neurocrine Biosciences, INC. | $88.19 | 2023-2024 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $65.57 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.89 | 2023 | |
| Bracco Diagnostics INC. | $17.88 | 2023 | |
| Sunovion Pharmaceuticals INC. | $12.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elmer Quintero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.